A Toronto cannabis firm is urging consumers to by wary of potential health risks in pot edibles and medicines that use nanotechnology, while at the same time unveiling a competitive product.
Trait Biosciences has developed technology to transform fat-based cannabinoids into water-soluble cannabinoids, which can then be produced commercially for food, beverages and nutraceuticals. It is set to unveil its cannabinoid products, in liquid and powder form, on Monday in California.
Meantime, several cannabis firms and labs have instead been pursuing nanotechnology as a means to infuse products with cannabinoids.
Trait uses glycosylation, which adds a sugar molecule to a cannabinoid molecule to make it water-soluble. The firm says its products affect people’s bodies faster than fat-based cannabinoids, and have increased stability, quality assurance and product shelf life.
Nanotechnology, on the other hand, produces tiny cannabinoid particles that are smaller than 200 nanometres (a strand of human hair is about 75,000 nanometres wide) to increase their bioavailability